Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.73 -0.10 (-0.63%)

Delayed Quote Updated: 11:58 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen ↗

September 26, 2025

Aurinia Pharmaceuticals (AUPH) is a top growth stock pick based on Louis Navellier's strategy, showing explosive earnings growth, strong sales momentum, and rising profit margins.

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum ↗

September 05, 2025

Aurinia Pharma (AUPH) shows strong growth momentum with surging earnings, impressive sales growth, and major margin expansion, making it a top pick for growth investors.

Via Chartmill

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Via Investor's Business Daily

Topics ETFs

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria ↗

August 15, 2025

Louis Navellier's growth strategy highlights Aurinia Pharmaceuticals (AUPH) for strong earnings momentum, rising revenue, and solid ROE—key traits for high-growth stock success.

Via Chartmill

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗

August 04, 2025

The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria.

Via Investor's Business Daily

Aurinia (AUPH) Q2 Revenue Jumps 22% ↗

July 31, 2025

Via The Motley Fool

Topics Intellectual Property

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

July 31, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

July 24, 2025

Aurinia Pharmaceuticals (AUPH) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, sales growth, and improving margins. The stock shows solid financial health and...

Via Chartmill

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

July 22, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

July 01, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy.

Via Chartmill

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

June 30, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results ↗

June 30, 2025

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Via Stocktwits

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

June 29, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

June 10, 2025

Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy.

Via Chartmill

US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert ↗

May 23, 2025

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.

Via Benzinga

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 22, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors ↗

May 19, 2025

Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors.

Via Chartmill

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance ↗

May 12, 2025

Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.

Via Benzinga

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens ↗

May 12, 2025

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Via Stocktwits

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 12, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview ↗

May 09, 2025

Via Benzinga

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

May 05, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

April 30, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

April 29, 2025

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Is AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) following the Minervini trend for explosive growth? ↗

March 29, 2025

Should you consider AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) for high growth investing? A fundamental and technical analysis of (NASDAQ:AUPH).

Via Chartmill

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet ↗

March 07, 2025

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.

Via Stocktwits

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations ↗

February 27, 2025

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.